Phase I clinical trial - Sein Adjuvant
MAGTRIVACSEIN - Projet MagTn3
Sein Adjuvant
Essai clinique fermé
Public cible
Adulte
An Open Label First-in-Human Adjuvant Phase I Study of a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri Tn Glycotop (MAG-Tn3) Plus AS15, as a Therapeutic Vaccine Candidate in Patients With Non Metastatic, HER2 Negative Localized Breast Cancer at High-Risk of Relapse
Description de l'essai
The purpose of this study is to evaluate if a maximum tolerated dose (MTD) can be obtained following 2 administrations of the MAG-Tn3 + AS15 cancer vaccine when administered at doses of 30 µg, 100 µg or 300 µg IM every three weeks.
Liens utiles
MARIE PAULE SABLIN
Investigateur principal